US$ 23.08
fda bpc-157 warning letter unapproved new drug issued 25 letters to telehealth companies for false and misleading claims about compounded GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of fda warning letter bpc-157 unapproved
Description
availability in the second half of 2025)
High doses might make optic nerve damage worse

This contrasts with GLP-1-based weight loss, where approximately 40% of total weight lost is lean tissue

Additional research must be conducted to determine the potential hazards and advantages of using this medicine over extended treatment durations for individuals facing chronic conditions
